小细胞肺癌精准治疗进展  

ADVANCES IN PRECISION THERAPY FOR SMALL CELL LUNG CANCER

作　　者：张凤[1] 姜曼[1] 周娜[1] 秦康 张晓春[1] ZHANG Feng;JIANG Man;ZHOU Na;QIN Kang;ZHANG Xiaochun(Oncology Precision Medicine Center, The Affiliated Hospital of Qingdao University, Qingdao 266061, China)

机构地区：[1]青岛大学附属医院肿瘤精准医学中心,山东青岛266061

出　　处：《精准医学杂志》2022年第2期184-188,共5页Journal of Precision Medicine

基　　金：山东省自然科学基金资助项目(ZR2018MH022)。

摘　　要：小细胞肺癌(small cell lung cancer,SCLC)是一种侵袭性强、预后差的高度恶性肿瘤。近年来,SCLC在精准治疗方面取得了重大突破。在免疫治疗中,程序性死亡配体-1(PD-L1)抑制剂阿替利珠单抗和度伐利尤单抗联合化疗一线治疗SCLC,使患者得到了长期的获益。程序性死亡受体-1(PD-1)抑制剂纳武利尤单抗和帕博利珠单抗相继被美国食品药品监督管理局(FDA)批准用于SCLC三线治疗。在靶向治疗领域,安罗替尼在SCLC三线及以上治疗中效果显著,阿帕替尼、奥拉帕利的临床试验也已经取得初步成果。本文主要综述了SCLC在精准治疗方面的进展,以期为SCLC患者带来新的希望。Small cell lung cancer(SCLC)is a highly aggressive and malignant tumor with poor prognosis.In recent years,a major breakthrough has been made in precision therapy for SCLC.In immunotherapy,the programmed death-ligand 1 inhibitors atezolizumab and durvalumab combined with chemotherapy are the first-line treatment of SCLC and have helped patients achieve long-term benefits.The programmed death-1 inhibitors nivolumab and pembrolizumab were successively approved by the U.S.Food and Drug Administration for the third-line treatment of SCLC.In the field of targeted therapy,anlotinib has shown a marked effect in the third-line or above treatment of SCLC,and preliminary results have been achieved in the clinical trials with apatinib and olaparib.This article mainly reviews the advances in precision therapy for SCLC,so as to bring new hope to the patients with SCLC.

关 键 词：小细胞肺癌 免疫检查点抑制剂 程序性细胞死亡受体1 程序性死亡配体-1 分子靶向治疗 精准医学 综述 

分 类 号：R734.2[医药卫生—肿瘤]